As several pharmaceutical companies challenge their role in the 340B drug pricing program, Bristol Myers Squibb filed a lawsuit Nov. 26 against the HHS agency that oversees the federal program.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
